Dutasteride, already FDA-approved to shrink a benign, enlarged prostate, reduced the risk of a prostate cancer diagnosis by 23% in high-risk men in a large, international trial, researchers reported in a recent issue of the New England Journal of Medicine.
After four years, the investigators found that dutasteride significantly reduced the chances that men would be diagnosed with the tumours in the mid-range (requiring aggressive treatment). These are the majority of all prostate cancers and they grow unpredictably, leading many men to opt for surgery or radiation therapy. These treatments can cause incontinence and impotence.
Read more.
Tags: Oncology
